Latest news with #HumanaInc
Business Wire
2 days ago
- Sport
- Business Wire
Humana Recognizes 10 Inspiring Athletes Who Are Redefining What It Means to Age
LOUISVILLE, Ky.--(BUSINESS WIRE)--As the presenting sponsor of the 2025 National Senior Games, leading health and well-being company Humana Inc. (NYSE: HUM) today announced the 2025 Humana Game Changers – a group of 10 remarkable athletes who exemplify healthy aging, resilience and the power of staying active in both body and mind. The Humana Game Changer program, launched in 2013, honors senior athletes who inspire others through their personal stories of perseverance, transformation and passion for wellness. Share This year's Games, taking place July 24–Aug. 4 in Des Moines, Iowa, mark Humana's 10th consecutive year as presenting sponsor and more than 15 years of partnership with the National Senior Games Association (NSGA). The biennial event brings together about 12,000 athletes aged 50 and up for an Olympic-style celebration of lifelong fitness. The Humana Game Changer program, launched in 2013, honors senior athletes who inspire others through their personal stories of perseverance, transformation and passion for wellness. The program has honored more than 100 senior athletes since its inception. The 2025 class includes athletes from across the country competing in sports such as pickleball, track and field, basketball and table tennis. 'These athletes are redefining what it means to age,' said George Renaudin, Humana's President of Insurance. 'They show us that staying active – physically, mentally and socially – can lead to a more vibrant, fulfilling life at any age.' Meet the 2025 Humana Game Changers: Madelaine 'Tiny' Cazel, 87 – Track and Field (The Villages, Florida) A National Senior Games veteran since 2003, Tiny competes in sprints, long jump, shot put and more. She helped pioneer women's sports in her community and continues to train weekly with unmatched energy. Her motto: stay active, stay curious, and surround yourself with support. Pamela DeLoatch, 62 – Pickleball (Apex, North Carolina) A writer and lifelong learner, Pamela discovered pickleball by chance and now competes in leagues and tournaments. She founded 'Black Girl Magic Pickleball' to create inclusive spaces for Black women to play and connect. Pamela balances her physical training with crochet, travel and meaningful conversations that keep her mind and spirit engaged. Dilip Desai, 83 – Table Tennis (Sugar Land, Texas) A structural engineer turned table tennis enthusiast, Dilip began competing in his 70s and has since become a fixture at the National Senior Games. A prostate cancer survivor managing osteoarthritis, he credits his success to 'mind over matter' and lives by the principles of determination, dedication and discipline. Off the court, he stays sharp through yoga, Bollywood dancing and mentoring greater Houston's youth. Ellen Demsky, 84 – Road Race, Track and Field, Power Walk, Triathlon (Tarzana, California) Ellen began running at 60 and has since completed more than 50 marathons – including four Boston Marathons and races on every continent. She now teaches courses on dementia prevention and iPhone photography at UCLA, blending physical and cognitive wellness. Her passion for movement and learning continues to inspire runners of all ages. Gail Eppley, 86 – 3-on-3 Basketball (Charlotte, North Carolina) A lifelong basketball player and coach, Gail now competes in 3x3 basketball while staying active with swimming, pickleball and yardwork. Despite multiple joint replacements, she remains fiercely competitive and mentally sharp through puzzles and games. With 13 grandchildren and eight great-grandchildren, Gail is a matriarch of movement and motivation. Jeremiah Hollis Jr., 71 – Pickleball (Redford, Michigan) A triple bypass survivor and Air Force veteran, Jeremiah found new purpose in pickleball after major surgeries. He's now a decorated competitor and advocate for heart health and active aging, especially within the Black community. Off the court, he's a golfer, puzzle-solver and community leader who believes in lighting the fire within others. James 'Jim' Hutchinson, 78 – Track and Field (Louisville, Kentucky) Inspired by a family legacy of runners, Jim has competed in track since childhood and continues to race despite past injuries. A retired entrepreneur and corporate leader, he volunteers to help community members with tax returns and keeps his mind sharp with Sudoku. After missing the 2023 Games due to injury, he's making a strong comeback in 2025. Denise Lawson, 59 – Track and Field (Springfield, Virginia) A lifelong runner and animal advocate, Denise returned to competitive track in her 50s after overcoming multiple injuries and a cardiac procedure. She trains alongside her retired sled dogs, whose energy and resilience inspire her every stride. Denise's story is a testament to joyful movement, second chances, and the healing power of staying active. Joni Neidigh, 66 – Road Race (Orange Park, Florida) A psychotherapist and hypnotherapist, Joni began running in the 1980s and returned after a long hiatus to reclaim her health and honor her late brother. She's lost 27 pounds, gained strength, and now helps others through sports hypnotherapy and public speaking. Joni challenges aging stereotypes and empowers others to find joy in movement. John White, 74 – Triathlon (Milwaukee, Wisconsin) A former professional football hopeful turned triathlete, John has completed more than 115 triathlons and 275 road races. He's a Wisconsin Senior Olympics Hall of Famer, educator and former NSGA board member who has dedicated his life to promoting fitness and inclusion. With his wife Mary, he travels the country racing and cheering on both the Wisconsin Badgers and the Green Bay Packers. To read more about the Class of 2025 and see all 114 Humana Game Changers, visit Humana Inc. (NYSE: HUM) is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we strive to make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at and at
Yahoo
30-04-2025
- Business
- Yahoo
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline
Humana Inc. (NYSE:HUM) on Wednesday posted a first-quarter adjusted EPS of $11.58, up from $7.23 a year ago, beating the consensus of $10.07. Humana sales increased from $29.6 billion to $32.11 billion, slightly missing the consensus of $32.22 billion. The revenue was driven by higher per-member Medicare and state-based contract premiums. The Medicare increase was primarily driven by an increased direct subsidy due to the Inflation Reduction Act (IRA) and membership growth in the company's stand-alone PDP and state-based contracts ended the first quarter with 14.84 million in total medical membership, down from 16.35 million in December 2024 and 16.17 million in March 2024. Individual Medicare Advantage membership reached 5.22 million, down from 5.55 million a year ago. 1Q25 Insurance segment benefit ratio of 87.4% aligns with the previously disclosed expectation of approximately 87.5%. In its prepared remarks, the company said, 'We are pleased with a solid start to 2025. Our first quarter Insurance segment benefit ratio of 87.4% reflects medical cost trends that developed in line with our expectations.' The company states, 'We remain committed to achieving an individual Medicare Advantage (MA) pretax margin of 'at least 3%' over time and remain confident in our expectation that our 2025 MA pricing will drive the intended underlying margin improvement.' Guidance: Humana expects 2025 GAAP sales of $126 billion-$128 billion versus the consensus of $126.21 billion. Sales guidance includes insurance segment sales of $121 billion—$123 billion and center-well segment sales of $20.5 billion—$21.5 billion. The company said CenterWell Pharmacy was selected as the fulfillment pharmacy for NovoCare Pharmacy, operated by Novo Nordisk A/S' (NYSE:NVS) weight loss medication for cash-pay customers. The insurer expects an annual membership decline of approximately 550,000 for individual Medicare Advantage, including the company's decision to exit certain unprofitable plans and counties. Group Medicare Advantage will remain relatively flat, and Medicare stand-alone PDP growth will be approximately 200,000. Humana reaffirms the 2025 adjusted EPS outlook of $16.25 versus the consensus of $16.35. For 2025, Humana expects its insurance segment's benefit ratio guidance of approximately 90.1-90.5%. The company added, 'Looking ahead, the 2026 final MA rate notice better reflects the medical cost trend environment and should enable greater stability within the industry as it serves the 34 million seniors who rely on the MA program.' Price Action: HUM stock is down 0.80% at $257.28 at the last check on Wednesday. Read Next:Photo by T. Schneider via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Washington Post
30-04-2025
- Business
- Washington Post
Humana: Q1 Earnings Snapshot
LOUISVILLE, Ky. — LOUISVILLE, Ky. — Humana Inc. (HUM) on Wednesday reported first-quarter earnings of $1.24 billion. The Louisville, Kentucky-based company said it had profit of $10.30 per share. Earnings, adjusted for one-time gains and costs, were $11.58 per share. The results beat Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of $9.98 per share.
Bloomberg
30-04-2025
- Business
- Bloomberg
Humana Affirms Guidance as Rising Medical Costs Sting Less
Humana Inc. reaffirmed its profit guidance for the year, a rare sign of relief in a US health insurance industry that has seen higher costs eating into profits. The Louisville, Kentucky-based insurer said Wednesday it still expects adjusted earnings of about $16.25 a share.
Business Wire
30-04-2025
- Business
- Business Wire
Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and net earnings per share (EPS) for the quarter ended March 31, 2025 (1Q25) versus the quarter ended March 31, 2024 (1Q24) as noted in the tables below. Diluted earnings per share (EPS) 1Q25 (a) 1Q24 (a) GAAP $10.30 $6.11 Amortization associated with identifiable intangibles 0.12 0.13 Put/call valuation adjustments associated with company's non-consolidating minority interest investments 1.35 1.08 Value creation initiatives 0.20 0.24 Impact of exit of employer group commercial medical products business — 0.01 Cumulative net tax impact (0.39) (0.34) Adjusted (non-GAAP) $11.58 $7.23 Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations. Expand Please refer to the tables above, as well as the consolidated and segment highlight sections in the detailed earnings release for additional discussion of the factors impacting the year-over-comparisons. 'Our team has done a great job launching us on a strong start to the year. Medicare Advantage is performing as expected and we are excited about our progress in expanding CenterWell and Medicaid,' said Humana President and CEO Jim Rechtin. 'We are confident in the growth outlook for value-based care and Medicare Advantage, which will allow us to provide more quality care to a broader group of patients and members." FY 2025 Earnings Guidance Humana revises its GAAP EPS guidance for the year ending December 31, 2025 (FY 2025) to 'approximately $14.68' from 'approximately $15.88', while affirming its Adjusted EPS guidance of 'approximately $16.25'. Diluted earnings per share FY 2025 Guidance FY 2024 (a) GAAP approximately $14.68 $9.98 Amortization associated with identifiable intangibles 0.49 0.50 Put/call valuation adjustments associated with the company's non-consolidating minority interest investments (b) 1.35 2.45 Value creation initiatives (b) 0.20 2.33 Impact of exit of employer group commercial medical products business — 1.19 Impairment charges — 1.65 Cumulative net tax impact (0.47) (1.89) Adjusted (non-GAAP) – FY 2025 projected (b); FY 2024 reported approximately $16.25 $16.21 Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations. Expand Detailed Press Release Humana's full earnings press release, including the statistical pages, has been posted to the company's Investor Relations site and may be accessed at or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at or on the company's website). Conference Call Humana will host a live question-and-answer session for analysts at 8:00 a.m. Eastern time today to discuss its financial results for the quarter and the company's expectations for future earnings. In advance of the question-and-answer session, Humana will post prepared management remarks to the Quarterly Results section of its Investor Relations page ( A webcast of the 1Q25 earnings call may be accessed via Humana's Investor Relations page at If you anticipate asking a question during the question-and-answer session, please register in advance at this link - Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID. The company suggests participants listening via the web or the conference call sign in or dial in at least 15 minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at approximately two hours following the live webcast. Footnotes The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company's core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent and uniform indicators of the company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. All financial measures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures. (a) For the periods covered in this earnings release, the following items are excluded from the non-GAAP financial measures described above, as applicable. Note each of the adjustments described below impacted FY 2024 Adjusted EPS as shown on page 2. Amortization associated with identifiable intangibles - Since amortization varies based on the size and timing of acquisition activity, management believes this exclusion provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments' income from operations. The table below discloses respective period amortization expense for each segment: Put/call valuation adjustments associated with the company's non-consolidating minority interest investments - These amounts are the result of fair value measurements associated with the company's primary care strategic partnership and are unrelated to the company's core business operations. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and EPS. Value creation initiatives - These charges relate to the company's ongoing initiative to drive additional value for the enterprise through cost saving, productivity initiatives, and value creation from previous investments, and primarily consist of asset impairment, severance charges, and external consulting spend specific to these initiatives. These charges were recorded at the corporate level and not allocated to the segments. For all periods shown within this earnings release, GAAP measures affected in this release include consolidated pretax results, EPS, and the consolidated operating cost ratio. Impact of exit of employer group commercial medical products business - These amounts relate to activity from the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023. For 1Q24, GAAP measures affected in this earnings release include consolidated pretax results, EPS, consolidated revenues, consolidated operating cost ratio, Insurance segment revenues, Insurance segment benefit ratio, Insurance segment operating cost ratio, and Insurance segment income from operations. Impairment charges - The company recognized non-cash impairment charges in 2024 related to certain indefinite-lived intangible assets based on the company's estimate of future financial performance in certain state markets. These charges were recorded at the corporate level and not allocated to the segments. No impact to 1Q25 or 1Q24 results. Cumulative net tax impact - This adjustment represents the cumulative net impact of the corresponding tax benefit or expense related to the aforementioned items excluded from the applicable GAAP measures. For all periods presented in this earnings release, EPS is the sole GAAP measure affected. In addition to the reconciliations shown on page 2 of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release: Revenues INSURANCE SEGMENT Revenues (in millions) 1Q25 1Q24 GAAP $30,937 $28,699 Impact of exit of employer group commercial medical products business — (279) Adjusted (non-GAAP) $30,937 $28,420 Expand Insurance Segment Benefit Ratio INSURANCE SEGMENT Benefit ratio 1Q25 1Q24 GAAP 87.4 % 89.3 % Impact of exit of employer group commercial medical products business — % 0.1 % Adjusted (non-GAAP) 87.4 % 89.4 % Expand Operating Cost Ratio CONSOLIDATED Operating cost ratio 1Q25 1Q24 GAAP 10.6 % 10.4 % Impact of exit of employer group commercial medical products business — % (0.1) % Value creation initiatives (0.1) % (0.1) % Adjusted (non-GAAP) 10.5 % 10.2 % Expand INSURANCE SEGMENT Operating cost ratio 1Q25 1Q24 GAAP 8.2 % 8.3 % Impact of exit of employer group commercial medical products business — % (0.1) % Adjusted (non-GAAP) 8.2 % 8.2 % Expand Insurance Segment - Income from Operations (b) FY 2025 projected Adjusted results exclude the future impact of items that cannot be estimated at this time. Cautionary Statement This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana's executive officers, the words or phrases like 'expects,' 'believes,' 'anticipates,' 'assumes,' 'intends,' 'likely will result,' 'estimates,' 'projects' or variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the 'Risk Factors' section of the company's SEC filings, a summary of which includes but is not limited to the following: If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana's profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient. If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the company's business may be materially adversely affected. The number of Humana's Medicare Advantage plans rated 4-star or higher will significantly decline in 2025. Humana has filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans, but there is no assurance that the company will prevail in this lawsuit. If the company is not successful, the decline in Star Ratings will negatively impact its 2026 quality bonus payments from CMS and may also significantly adversely affect the company's revenues, operating results, and cash flows. In addition, there can be no assurances the company will be successful in maintaining or improving its Star Ratings in future years. If Humana, or the third-party service providers on which it relies, fails to properly maintain the integrity of its data, to strategically maintain existing or implement new information systems, to protect Humana's proprietary rights to its systems, or to defend against cyber-security attacks, contain such attacks when they occur, or prevent other privacy or data security incidents that result in security breaches that disrupt the company's operations or in the unintentional dissemination of sensitive personal information or proprietary or confidential information, the company's business may be materially adversely affected. Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company's cost of doing business. As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts; governmental audits and investigations; potential inadequacy of government determined payment rates; potential restrictions on profitability, including by comparison of profitability of the company's Medicare Advantage business to non-Medicare Advantage business; or other changes in the governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a "Fee for Service Adjuster" could have a material adverse effect on the company's operating results, financial position and cash flows. Humana's business activities are subject to substantial government regulation. New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company's cost of doing business and have a material adverse effect on Humana's results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company's ability to expand into new markets, increasing the company's medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company's Medicare payment rates and increasing the company's expenses associated with a non-deductible health insurance industry fee and other assessments); the company's financial position (including the company's ability to maintain the value of its goodwill); and the company's cash flows. Humana's failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company's results of operations, financial position, and cash flows. If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company's business may be adversely affected. Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company's success, and its failure to do so could adversely affect the Company's businesses, operating results and/or future performance. Humana's pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses. Changes in the prescription drug industry pricing benchmarks may adversely affect Humana's financial performance. Humana's ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations. Downgrades in Humana's debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition. Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio. In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements. Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance: Form 8-Ks filed during 2025. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at and at
